Left: G-banded partial karyogram at relapse, showing the inv(11)(p15q22) and del(20)(q11). Right: FISH result using centromeric XY DNA probe (Vysis) after the second HCT showing 99.8% XY signal (donor-originated). 
Other Molecular Studies
Technics: RT-PCR: Not done because no sample left to extract RNA.
Comments
Inversion (11)(p15q22) is a rare entity. It has been found as abnormal clone in MDS or myeloid leukemia, either de novo or secondary, in both children and adults. There seems to be male predominance. To our knowledge, this is the first case report that presents inv(11)(p15q22) as an additional cytogenetic abnormality besides deletion 20q, a common aberration in MDS. Previously, Yamamoto M et al reported the appearance of an inv(11)(p15q22) as a secondary anomaly in a chronic myeloid leukemia (CML) patient undergoing treatment with imatinib, suggesting a possibility that this abnormality might be involved in drug resistance and disease evolution. Our patient was diagnosed as MDS-RAEB with isolated deletion 20q at admission. One month after unrelated donor HCT, the patient reached complete hematologic and cytogenetic remission. However, about four months after transplantation, myeloblasts recurred in the bone marrow. Flow cytometry examination revealed about 10% abnormal cells with characteristic immunophenotype of myeloblasts. Cytogenetical detection revealed two abnormal clones, one with sole deletion 20q, the other with inv(11)(p15q22) and other aberrations besides deletion 20q. We speculate the occurrence of inv(11)(p15q22) with two possibilities: (1) clonal evolution, because the patient had isolated deletion 20q at initial diagnosis, which is common in MDS patients. In general condition, clonal evolution means disease progression and leukemic transformation in MDS, so acquisition of inv(11)(p15q22) might be a cause of relapse after HCT.
(2) therapy-related aberration, as the patient received high-dose pretreatment before donor stem cell infusion, although this is unlikely. Until now 13 cases with inv(11)(p15q22) have been reported by literature review (Table 1) . This inversion leads to fusion of DDX10, a putative RNA helicase gene at 11q22 with the nucleoporin gene NUP98 at 11p15.
The previously described cases with this chromosome anomaly and NUP98-DDX10 fusion gene comprising 5 children,7 adults and 1 unknown. 8 cases had diagnosis of de novo or secondary AML, 4 cases had primary or therapy-related MDS, and one CML case was found with this chromosome abnormality in acute phase. NUP98-DDX10 fusion, another type of NUP98 rearrangements, might be associated with the poor clinical course.
